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In August 2016, several leaders in glucagon biology gathered for the European Association for the
Study of Diabetes HagedornWorkshop in Oxford, England. A key point of discussion focused on the
need for basal insulin to allow for the therapeutic benefit of glucagon blockade in the treatment of
diabetes. Among the most enlightening experimental results presented were findings from studies
in which glucagon receptor–deficient mice were administered streptozotocin to destroy pancreatic
b cells or had undergone diphtheria toxin–induced b cell ablation. This article summarizes key
features of the discussion as a consensus was reached. Agents that antagonize glucagon may be of
great benefit for the treatment of diabetes; however, sufficient levels of basal insulin are required
for their therapeutic efficacy. (Endocrinology 158: 696–701, 2017)
Hyperglucagonemia and dysregulated glucagon se-cretion have been implicated in contributing to
hyperglycemia in patients with type 1 (1, 2) and type 2
(3–5) diabetes mellitus. These observations have sup-
ported continued efforts aimed at understanding the
bihormonal relationship between insulin and glucagon
and the investigation of glucagon-based therapeutic ap-
proaches. Herein, we reviewmuch of the seminal work in
glucagon biology and highlight recent mechanistic studies
that elegantly use the glucagon receptor–deficient mouse
model to further assess the ability of blocked glucagon
signaling to counteract insulin deficiency.
Glucagon was originally isolated as a hyperglycemic
substance (6). When the radioimmunoassays became
available (7), it was revealed that glucagon secretion was
inversely regulated by plasma glucose concentrations (8),
supporting its role as a major glucose-regulating hor-
mone. Studies of fasting patients with type 1 diabetes who
were maintained at near euglycemia with insulin in-
fusions demonstrated that plasma glucose and ketone
levels increased rapidly after termination of the insulin
infusion; importantly, this was paralleled by increases of
plasma glucagon concentrations (9). Furthermore, if
somatostatin (which strongly inhibits glucagon secretion)
was infused simultaneously, the rise in not only glucagon
but also plasma glucose and ketones could be strongly
reduced, but not when glucagon was replaced (1, 9).
These and several other related observations led Unger
and Orci (10) to propose in 1975 that diabetic hyper-
glycemia in general was inseparably associated with
inappropriate/unopposed glucagon secretion. This pro-
posal caused considerable debate, particularly regarding
the pathophysiology of type 1 diabetes; the existing
dogma—that the clinical features of the disease were
entirely due to lack of insulin—was not easily abandoned.
The strongest support for the traditional belief was from
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demonstrations of missing or inappropriately low se-
cretion of insulin in patients with diabetic ketoacidosis
and the observation of immediate relief of the condition
upon insulin administration.
In 1977, Barnes et al. (11), using advanced (for the
time) assay technology, reported full-scale development
of diabetic ketoacidosis in totally pancreatectomized
subjects without measurable glucagon secretion, leading
the authors to conclude that glucagon is not essential for
the development of ketoacidosis in diabetes. At that time,
several reports had shown production of glucagon from
extrapancreatic sites in experimental animals (in partic-
ular cats and dogs) (12), but in Barnes and colleagues’
patients, glucagon levels were immeasurable. This finding
suggested that extrapancreatic secretion of glucagon
might not occur in people. However, Ravazzola et al. (13)
identified glucagon-positive cells in the human stomach
that showed ultrastructure features consistent with an
a cell, indicating that humans may indeed have extra-
pancreatic glucagon, which could contribute to hy-
perglycemia. Subsequent research with even more
sophisticated techniques has now demonstrated that
pancreatectomized patients may have remarkably large
amounts of glucagon secreted from the gastrointestinal
tract (14). Therefore, it remains possible that glucagon
can contribute to the diabetic phenotype, even in patients
with total pancreatectomy.
For many years, it was tacitly accepted that glucagon
might play a role, but that the lack of insulin was believed
to be the predominant hyperglycemic factor in diabetes,
and this remained textbook dogma. However, the evi-
dence for a role for glucagon was intriguing enough to
spur interest in developing antagonists of glucagon ac-
tion, and many (generally futile) attempts at this were
made. Initially, these were mainly peptide-derived glu-
cagon receptor antagonists that were invariably partial
agonists, and the antagonistic effect was not sufficiently
robust (15). However, evidence started to mount that
glucagon might also play a role in the hyperglycemia of
type 2 diabetes, including important pioneering studies
from the laboratories of Alain Baron (4) and Robert
Rizza (16). To provide proof of concept for the use of
glucagon antagonism in diabetes, Brand et al. (17) nor-
malized blood glucose of mildly alloxan diabetic rabbits
(a type 2 diabetes–like model) by administration of a
high-affinity monoclonal glucagon antibody, which
could effectively neutralize circulating glucagon activity.
The same antibody could also normalize glycemia in
intermediate-dose streptozotocin (STZ)-diabetic rats (a
type 2 model), but it was ineffective in animals with more
severe diabetes caused by high-dose STZ (a type 1 model)
(18). This supported the general concept regarding the
role of glucagon in contributing to hyperglycemia but
also indicated that there may be a minimal insulin re-
quirement for glucagon antagonism to be effective.
These and other studies provided further impetus to
develop glucagon receptor antagonists, and several
pharmaceutical companies became engaged in the hunt.
Support for those pursuits was bolstered by findings from
studies characterizing a new experimental model: the
glucagon receptor (Gcgr2/2) knockout mouse (19, 20).
These animals showed lower blood glucose levels and
significantly improved glucose tolerance but displayed
similar insulin levels compared with control mice, further
supporting the glucagon pathway as a therapeutic target.
Soon thereafter, glucagon receptor antisense oligonu-
cleotides (ASOs) were demonstrated to robustly reduce
hyperglycemia in several rodent models of type 2 diabetes
(21, 22). In agreement with effects of the glucagon-
neutralizing antibodies, Gcgr null mice or normal ani-
mals administered the glucagon receptor ASOs did not
develop hypoglycemia; only amild lowering of fasted and
fed plasma glucose concentrations was observed. On the
basis of the lack of severe hypoglycemia, the lesson
learned was that glucagon antagonism appears relatively
safe and therefore a potential therapy for type 2 diabetes.
In subsequent years, several small molecule glucagon
receptor antagonists were developed and shown to act as
powerful (oral) antidiabetic agents in both preclinical and
clinical studies of type 2 diabetes (23). The appearance of
unexpected side effects [increasing plasma levels of glu-
cagon (see later), hepatic aminotransferases, and low-
density lipoprotein (24)] halted development of some but
not all of these molecules. Importantly, the clinical results
with the antagonists demonstrated unequivocally that
inappropriate secretion of glucagon is responsible for a
major part of the hyperglycemia of type 2 diabetes (24).
On this background, it was little less than a sensation
when in 2011 Lee et al. (25) from the laboratory of Roger
Unger reported that inGcgr2/2mice [developed byGelling
et al. (20)], repeat doses of STZ did not cause a diabetic
phenotype. The same group subsequently showed (26)
that reconstitution of hepatic glucagon receptors in these
mice by adenovirus-mediated delivery resulted in a full-
blown diabetic state, which resolved as the transgene
expression waned. Further studies showed a similar effect
in normal mice by using a glucagon receptor antagonist
antibody (27). These findings provided new fuel to the old
hypothesis that glucagon is responsible for diabetic hy-
perglycemia, and the old debate flared up again: What is
more important—lack of insulin or excess of glucagon?
This discussion was a major theme at a European
Association for the Study of Diabetes–sponsored sym-
posium on glucagon recently held in Oxford, England
(21st European Association for the Study of Diabetes
Hagedorn Oxford Workshop: Glucagon, the Alpha Cell
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and Intraislet Paracrine Relationships; chairs: Jens Juul
Holst and Patrik Rorsman, August 2016), with repre-
sentatives from many of the groups that had been en-
gaged in this debate and had carried out experimental
work to understand these new observations. Several
studies were presented, and at the final discussion, a
consensus was reached about the probable mechanisms
behind the observations from Roger Unger’s and several
other laboratories.
First, let us consider more of the important published
results on this theme. Thorel et al. (28), from the labo-
ratory of Pedro Herrera, produced acute glucagon de-
ficiency by using diphtheria toxin in transgenic animals
expressing the human diphtheria toxin receptor under
control of the proglucagon promoter. These animals lost
almost all of their a cells, but the phenotype was un-
remarkable; however, hyperglycemia after STZ admin-
istration was not prevented by the glucagon cell ablation.
The authors concluded that the small amount of pan-
creatic glucagon left after the glucagon cell ablation must
be sufficient to maintain the metabolic effects of gluca-
gon, including the type 1–like diabetic phenotype
resulting from STZ treatment. Similarly, Steenberg et al.
(29) also generated acute glucagon cell–depleted mice by
using diphtheria toxin, but the massive reduction in
pancreatic glucagon cells and glucagon content did not
result in improvement of the severe type 1 diabetic
phenotype after large doses of STZ. Inspired by the
conclusion of Thorel et al. (28) that even a small amount
of glucagon would suffice to produce the metabolic ef-
fects of glucagon, these investigators also administered a
glucagon-neutralizing antibody [the same monoclonal
antibody as used in the original studies by Brand et al.
(18)], as well as a glucagon receptor antagonist, pre-
viously shown to potently antagonize glucagon action in
vivo (30). However, neither approach was able to resolve
the hyperglycemia.
Additional important contributions to the discussion
were data provided by Damond et al. in April 2016 (31).
These authors hypothesized that incomplete destruction of
b cells might underlie some of the differences observed in the
various prior studies. Using traditional STZ treatment in
Gcgr2/2 mice, they reproduced the observations of
complete absence of hyperglycemia (Fig. 1, inverted purple
triangles). However, realizing that after conventional STZ
treatment a residual b cell mass was present and thus
insulin secretion remains, these investigators used a
diphtheria toxin ablation approach that had previously
been shown to result in near-total b cell ablation (32).
Importantly, now after diphtheria toxin–induced ablation,
full-blown diabetes developed in the Gcgr2/2 mice. Sim-
ilarly, insulin blockade with the potent insulin receptor
antagonist S961 administered after conventional STZ
treatment resulted in development of a full type 1 diabetic
phenotype in theGcgr2/2mice (Fig. 1, purple diamonds).
Similar observations have been made by researchers in the
Holland and Unger laboratories using the PANIC ATTAC
mouse, a model of triggered b cell apoptosis. Here, glu-
cagon receptor antagonist antibodies failed to lower blood
glucose in severely diabetic PANICATTACmice (Holland
and Unger, unpublished observations). Very recently,
Neumann et al. (33) assessed mice with double knockout
for the insulin and glucagon receptor genes kept alive with
exogenous insulin and islet transplants; these studies in-
dicated that the metabolic manifestations associated with
complete lack of insulin cannot be overcome by Gcgr
inactivation and that lack of glucagon signaling was as-
sociated with modest reductions in blood glucose and
ketones but not survival. Taken together, the cumulative
evidence from all of these studies indicates that lack of
glucagon signaling efficiently compensates for the conse-
quences of insulin insufficiency, but only if residual insulin
action persists after b cell loss.
It has been proposed that secretion of a cell–generated
glucagon-like peptide-1 (GLP-1) might contribute to
some of the antidiabetic effects of attenuated glucagon
signaling. In agreement with the original findings by
Gelling et al. (20), Steenberg et al. (29) noted that the
Gcgr2/2 mice develop massive a cell hyperplasia and
hypersecretion of glucagon (the same is observed after
glucagon-neutralizing antibody, glucagon receptor an-
tagonist antibody, or glucagon receptor ASO adminis-
tration). Similar findings are made in humans with
inactivating mutations in the glucagon receptor (34).
Figure 1. Gcgr2/2 mice become hyperglycemic after efficient insulin
signaling blockade. Unlike their Gcgr+/2 counterparts, Gcgr2/2
animals remain normoglycemic after two STZ injections (blue versus
purple inverted triangles) but develop hyperglycemia after
additional insulin blockade with the insulin receptor antagonist S961
(purple diamonds). Mice were injected with STZ at days 0 and 7
(200 and 150 mg/kg, respectively) to ablate b cells and/or treated
with S961 between days 15 and 21 (osmotic pump, 40 nmol) to
inhibit insulin signaling. Random-fed glycemia is shown. Modified
from Damond et al. (31).
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Interestingly, the hyperplastic islets in mice also appear to
produce GLP-1 (another product processed from pro-
glucagon). This finding is in line with original observa-
tions by both the Bloom and Habener laboratories
suggesting that proglucagon processing in islets generates
some a cell–derived GLP-1 (35, 36). The potential in-
volvement of a cell–produced GLP-1 in antidiabetic ef-
fects was first supported by the glucagon receptor ASO
experiments (22) and later by studies with a glucagon
receptor antagonist antibody (37). The role of GLP-1 in
glucose lowering that results from blunting glucagon
signaling was investigated by Jun et al. (38) from the Eli
Lilly and Co. laboratories using a double-knockout
mouse model harboring deletion of both Gcgr and
Glp1r. Similar to Unger’s findings, these studies showed
that STZ-induced diabetes did not develop in Gcgr2/2
mice. However, in the double-knockout mice, the same
STZ treatment resulted in substantial hyperglycemia,
amounting to about half of that seen in control mice given
STZ (38). Also, administration of a glucagon receptor
antagonizing antibody reversed hy-
perglycemia in STZ-treated mice [in
agreement with results from Wang
et al. (27) using a different antibody],
but importantly, the antibody was only
partially effective in Glp1r2/2 mice
(38). Judging from these results, ac-
tions exerted via the GLP-1 receptor
appear to play an important role in the
glucose-lowering phenomenon. There-
fore, increased a cell–produced GLP-1
might be responsible for some of the
antidiabetic effects of glucagon block-
ade, independent of its insulinotropic
actions. Traditionally, GLP-1 is not
thought to influence hepatic glucose
production, but this has been challenged
in recent studies (39), in which GLP-1
appeared to directly inhibit hepatic
glucose production in mice and humans
(40, 41).
Can the GLP-1 hypothesis also ex-
plain part of the efficacy demonstrated
by glucagon receptor antagonist anti-
bodies, which appear to be nearly as
effective as Gcgr knockout in pre-
venting STZ-induced hyperglycemia?
As mentioned earlier, there is little
doubt that strong glucagon antago-
nism results in a cell hyperplasia and
hyperglucagonemia in rodents (22, 38)
and nonhuman primates (42). Pre-
vention of glucagon action by glucagon
receptor antibodies in humans would, therefore, be ex-
pected to have similar results. With the currently avail-
able data, it is unclear whether there are significant
differences in the degree and rate of a cell proliferation
induced by glucagon receptor antagonist antibodies in
rodents versus primates, and the implications of a cell
hyperplasia following long-term treatment need to be
carefully assessed. Furthermore, the kinetics of GLP-1
secretion by a cells after blocking of glucagon signaling
also needs investigating.
The consensus conclusion from the total body of work is
that complete lack of insulin, as in severe long-standing type
1 diabetes, locks the liver in a state where blunting of
glucagon action is unable to downregulate glucose pro-
duction. However, this applies only to conditions of
severe insulin deficiency. Experimentally, a threshold
seems to exist in the severity of diabetes, above which
only insulin or combinatorial treatment can effectively
normalize blood glucose. Perhaps this threshold is co-
incident with ketosis, as b cell depletion sufficient to
Figure 2. The lack of glucagon action mitigates hyperketonemia development after b cell
ablation. In mice with normal glucagon signaling, diphtheria toxin–mediated b cell
destruction leads to a sharp increase in circulating levels of ketone bodies. This increase is
attenuated but not entirely abolished in b cell–ablated Gcgr2/2 mice. The corresponding
random blood glucose levels averaged over 1 month are shown on the lower panel.
Experimental procedures were performed as described (31). Briefly, adult (10–12 weeks old)
RIP-DTR;Gcgr2/2 males (20, 31) were injected with diphtheria toxin to induce b cell ablation.
One month later, b-hydroxybutyrate levels were measured from plasma using an enzymatic assay
(MAK041, Sigma-Aldrich). Error bars indicate SEM. *P , 0.05 and **P , 0.01 versus unablated
Gcgr+/2 mice; ## P , 0.01; b cell–ablated: Gcgr+/2 versus Gcgr2/2, Mann-Whitney U test.
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induce ketosis cannot be completely restored by glucagon
antagonism. The control of ketogenesis is equally im-
portantly regulated, and some observations suggest that
ketogenesis may be more selectively dependent on glu-
cagon action than glucose production (43). It is important
to note that ketosis was reduced in further studies of
the diphtheria toxin b cell–ablated Gcgr2/2 animals
[Damond et al. (31); Fig. 2] in agreement with obser-
vations that Gcgr gene deletion attenuated hyper-
ketonemia in InsKO pups (33). Given the important role
of glucagon signaling in regulating hepatic lipid oxida-
tion (44), it will be important to determine whether
chronic treatment with glucagon antagonists promotes
hepatosteatosis.
In the entire interval of relative insulin insufficiency,
which covers late-stage type 2 diabetes and probably also
type 1 diabetes with residual insulin production, (in-
appropriate) glucagon levels are responsible for hepatic
glucose production to an extent, where a complete
normalization of glucose levels may be achieved if glu-
cagon actions are prevented. Therefore, glucagon an-
tagonism remains an important target for antidiabetic
therapy in conditions where basal insulin action remains
and should be further investigated (44).
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